Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price traded down 33.3% during mid-day trading on Friday . The company traded as low as C$0.02 and last traded at C$0.02. Approximately 1,200,000 shares changed hands during mid-day trading, an increase of 1,995% from the average session volume of 57,275 shares. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Down 33.3%
The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40. The firm has a market capitalization of C$3.38 million, a PE ratio of 0.67 and a beta of -0.09. The company has a fifty day moving average price of C$0.03 and a 200-day moving average price of C$0.03.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Read More
- Five stocks we like better than Quest PharmaTech
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
